FRAX® with and without Bone Mineral Density

FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

(2010) O. Ström et al.   BONE

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®

(2010) John A. Kanis et al.   BONE

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The US FRAX® filter: avoiding confusion or hindering progress?

(2010) E. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Filtering FRAX®

(2010)   OSTEOPOROSIS INTERNATIONAL

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women

(2010) John A. Kanis et al.   Archives of Osteoporosis

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

FRAX® and its applications to clinical practice

(2009) John A. Kanis et al.   BONE

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density

(2009) Richard Eastell et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FRAX® assessment of osteoporotic fracture probability in Switzerland

(2009) K. Lippuner et al.   OSTEOPOROSIS INTERNATIONAL

BMD, clinical risk factors and their combination for hip fracture prevention

(2009) H. Johansson et al.   OSTEOPOROSIS INTERNATIONAL

Health economics of osteoporosis

(2008) Fredrik Borgström et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis

(2008) Bess Dawson-Hughes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)

(2008) S. Fujiwara et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks

(2008) N. D. Nguyen et al.   OSTEOPOROSIS INTERNATIONAL

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

(2008) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

The incidence and risk of hip fracture in Poland

(2008) E. Czerwinski et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL